One Company May Hold the Key to Alzheimer’s Treatment

Dear Wall Street Daily Reader,

Alzheimer’s is one of the most heartbreaking diseases out there.

Turning loved ones into shells of their former selves with the side effects of dementia…

And in the end taking their life.

Nearly 6 million Americans suffer from Alzheimer’s as of 2020 — a figure that may rise to 14 million by 2050 as life expectancy continues to increase.

Big pharmaceutical companies over the past decade have thrown billions of dollars into trying to get some sort of progress toward a cure for Alzheimer’s and dementia.

Names like Pfizer and Johnson & Johnson and countless public research institutions and universities have all tried their hand at a cure.

But none has succeeded.

And because these attempts have been so costly, many of these companies have ended their initial programs to tackle this disease.

There are two big problems when it comes to treating Alzheimer’s.

The first problem lies in not fully understanding exactly what the disease is or what causes it.

For years, everyone in the medical community thought that targeting a protein called beta amyloid was the solution.

This buildup of proteins in the brain clumped together to make “senile plaques.”

But since targeting these proteins with the current methods wasn’t working, they abandoned their programs to find a cure.

The second major hurdle was getting a drug to make it past the blood-brain barrier.

The blood-brain barrier acts as a way to stop invasive drugs or toxins making it into the brain — the exact place where these beta proteins were building up and causing dementia and Alzheimer’s.

This meant that even if there were a drug out there that could get rid of the plaque buildup…

You wouldn’t be able to properly get it to work.

With all of this doom and gloom it’s hard to think of the positives in this situation.

But there’s still hope out there…

A handful of tiny biotech companies are working on ways to get around these hurdles.

In fact, I’ve targeted one in particular that I think has the best shot. Their Stage 3 clinical trial results could mean huge things for finding a treatment for Alzheimer’s.

This checks all the boxes for me when it comes to investing. Like I’ve said before…

You get the most out of your investments by putting money in companies doing the most good for the world.

There’s only so much a paper-making company can do besides private donations…

But a biotech company with the potential to solve the cure for cancer?

Now, that’s something that’ll not only change the world forever…

But it will get that company a name in history.

And it will make revenue for them skyrocket in the meantime.

I myself have targeted a company that I think has the key to unlocking a treatment for Alzheimer’s.

Their method is unconventional…

But I believe that if their next clinical trial goes well, they could take the next step and easily apply it to try to treat this deadly disease.

And if that happens, you could be there along the ride the whole way

Not only with the potential to make a huge windfall of cash…

But also with the knowledge that you helped fund a company working to develop a treatment for Alzheimer’s.

To get more information on this amazing opportunity, click here right now.

To a bright future,

Ray Blanco
Editor, Technology Profits Confidential
Seven Figure Publishing

You May Also Be Interested In:

Time Is Still on Our Side in This Crazy Housing Market

Stansberry Research editor, Dr. Steve Sjuggerud shares: “My wife bought a house near our home in Florida three years ago. Her plan was to renovate it and sell it for a profit. Instead of a $100,000 profit, she made more than a $200,000 profit. But this crazy market doesn't have to end. Let me explain…”

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Profit Alert, Ray Blanco’s Catalyst Traderand Technology Profits Daily. Ray has been with Seven Figure Publishing for ten years. In 2020, his closed positions in Technology Profits Confidential averaged over 91% gains.

View More By Ray Blanco